Home / Market News / $AGEN
fiscal.ai Corporate Catalyst Impact 85/100 ● positive

Agenus Reports Positive Phase 2 Results for BOT+BAL in NEOASIS Study at ESMO 2026

Oct 26, 2026, 1:04 AM UTC · Primary ticker $AGEN

Agenus announced highly positive early Phase 2 results for its combination therapy BOT+BAL in dMMR colon cancer, showing a 72% pathological complete response rate. This strong efficacy data could significantly de-risk the therapy and boost investor confidence in Agenus's oncology pipeline.

Agenus reported compelling early Phase 2 results for its BOT+BAL combination therapy in dMMR colon cancer, with 72% of patients achieving no remaining cancer after treatment. This high pathological complete response rate is a significant positive signal, suggesting strong efficacy for a difficult-to-treat cancer. This news is a major catalyst for Agenus, potentially increasing its valuation and attracting further investment. In the short term, Agenus's stock is likely to see a positive reaction. Long-term, these results could pave the way for accelerated development and potential market entry, offering a new treatment option for dMMR colon cancer patients and solidifying Agenus's position in the immuno-oncology space. The key opportunity for traders is the potential for significant upside in AGEN shares.

$AGEN positive Positive clinical trial results
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.